Cardiovascular Risk Factors when Using Modern Chemotherapy Regimens in Comorbid Patients with Multiple Drug-Resistant Tuberculosis
https://doi.org/10.58838/2075-1230-2025-103-3-40-46
Abstract
The objective: to evaluate predictors of cardiotoxicity when using modern chemotherapy regimens in comorbid patients with multiple drug-resistant tuberculosis (MDR TB) to identify a group facing a high risk of cardiovascular events.
Subjects and Methods. A single-center, open-label, controlled prospective cohort study was conducted. A total of 87 MDR TB patients were enrolled and divided into 2 groups: Group 1 included 24 patients whose QT interval length exceeded 450 ms at one or more control points; Group 2 included 63 patients whose QT interval duration length was less than 450 ms at all observation periods.
Results. In this study, traditional risk factors for QT prolongation, such as: overweight or underweight, smoking, hypokalemia, bradycardia, taking two QT-prolonging anti-tuberculosis drugs (fluoroquinolone and bedaquiline) and in combination with capreomycin, did not provide a significant effect on the development of cardiotoxic reactions during anti-tuberculosis chemotherapy. The risk of QT prolongation and related cardiovascular complications was significantly associated with comorbid cardiovascular diseases (CVD) (OR=4.29, CI 1.46–12.56; p=0.009), a family history of CVD (OR=4, CI 1.26–12.72; p=0.024), chronic obstructive pulmonary disease (OR=2.9, CI 1.1–7.67; p=0.033), and female gender (OR=3.73, CI 1.38–10.07; p=0.015). The identified predictors, even at the stage of compiling an anti-tuberculosis regimen, make it possible to identify a risk group for developing cardiotoxic reactions among MDR TB patients.
About the Authors
E. M. Zhukova
Novosibirsk Tuberculosis Research Institute, Russian Ministry of Health
Russian Federation
Russian Federation
Elena M. Zhukova, Doctor of Medical Sciences, Leading Researcher
Phone: +7 (383) 203-78-25
81a Okhotskaya St., Novosibirsk, 630040
O. A. Serov
Novosibirsk Tuberculosis Research Institute, Russian Ministry of Health
Russian Federation
Russian Federation
Oleg A. Serov, Candidate of Medical Sciences, Senior Researcher
Phone: +7 (913) 946-06-46
81a Okhotskaya St., Novosibirsk, 630040
References
1. Auchinka V.P. Effectiveness and safety of delamanid-containing regimens in patients with drug-resistant tuberculosis and cardiovascular comorbidities. Emergency Cardiology and Cardiovascular Risks, 2022, vol. 6, no. 2, pp. 1604-1610. (In Russ.)
2. Zhukova E.M., Vokhminova L.G., Kudlay D.A. The effect of the current chemotherapy of MDR/XDR tuberculosis on QT interval changes in ECG. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 11, pp. 19-22. (In Russ.) http://doi.org/10.21292/2075-1-230-2019-97-11-19-22
3. Ivanova D.A., Borisov S.E., Rodina O.V., Filippov A.V., Ivanushkina T.N., Litvinova N.V. Safety of treatment regimens for multiple drug resistant tuberculosis patients compiled as per the new WHO recommendations as of 2019. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 1, pp. 5-15. (In Russ.)
4. Klinicheskiye rekomendatsii po kardiologii i komorbidnym boleznyam. [Guidelines for cardiology and comorbid diseases]. F.I. Belyalov, eds., 2nd ed., reviewed and supplemented, Moscow, GEOTAR-Media Publ., 2021.
5. Komissarova S.M., Rineyskaya N.M., Sevruk T.V., Efimova A.A. Risk factors for the development of adverse cardiovascular events in patients with a combination of non-compaction and dilated cardiomyopathy. Emergency Cardiology and Cardiovascular Risks, 2022, vol. 6, no. 2, pp. 1615-1624. (In Russ.)
6. Kulchavenya E.V., Kholtobin D.P., Zhukova E.M. Are fluoroquinolones dangerous? Pharmacology & Pharmacoterapy, 2023, no. 4, pp. 96-102. (In Russ.) https://doi.org/10.46393/27132129_2023_4
7. Mozhokina G.N., Samoylova A.G., Vasilyeva I.A., Abramchenko A.V. Delamanid: safety and efficacy analysis. Tuberculosis and Lung Diseases, 2023, vol. 101, no. 6, pp. 102-110. (In Russ.)
8. Nikolenko N.Yu., Kudlay D.А., Doktorova N.P. Pharmacoepidemiology and pharmacoeconomics of multidrug- and extensively drug-resistant tuberculosis. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology, 2021, vol. 14 (2), pp. 235-248. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.089.
9. Ostroumova O.D., Goloborodova I.V. Drug-induced long QT interval: prevalence, risk factors, treatment and prevention. Consilium Medicum, 2019, vol. 21, no. 5, pp. 62-67. (In Russ.) https://doi.org/10.26442/20751753.2019.5.190415
10. Skryagina E.M., Gurevich G.L., Solodovnikova V.V., Dyusmikeeva M.I., Setkina S.B., Zhurkin D.M. Experience of treating multiple/extensive drug resistant tuberculosis with new regimens in Belarus Republic. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 8, pp. 5-14. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-8-5-14
11. Smolyakova M.V., Grigorenko E.A., Kalachik O.V., Mitkovskaya N.P. Cardiovascular risk factors of preoperative and long-term postoperative period in kidney transplant recipients. Emergency Cardiology and Cardiovascular Risks, 2020, vol. 4, no. 1, pp. 846-852. (In Russ.)
12. Tuberkulez u vzroslykh. Klinicheskie rekomendatsii). [Tuberculosis in adults. ( Guidelines)]. Moscow, 2022, 151 p.
13. Auchynka V., Kumar A.M.V., Hurevich H., Sereda Y., Solodovnikova V., Katovich D., Setkina S., Yedilbayev A., Skrahin A., Skrahina A. Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18. Monaldi Arch Chest Dis., 2021, vol. 91, no. 1S.
14. Cardinale D., Iacopo F., Cipolla C.M. Cardiotoxicity of anthracyclines. Front Cardiovasc. Med., 2020, vol. 7, no. 26, pp. 1-14. https://doi.org/10.3389/fcvm.2020.00026
15. Das M., Dalal A., Laxmeshwar C., Ravi S., Mamnoon F., Meneguim A.C. et al. one step forward: successful end-of-treatment outcomes of patients with drug-resistant tuberculosis who received concomitant bedaquiline and delamanid in Mumbai, India. Clin. Infect. Dis., 2021, vol. 73, no. 9, pp. 3496–e3504.
16. Ferlazzo G., Mohr E., Laxmeshwar C., Hewison C., Hughes J., Jonckheere S., Khachatryan N., De Avezedo V., Egazaryan L., Shroufi A., Kalon S., Cox H., Furin J., Isaakidis P. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infect Dis., 2018, vol. 18, no. 5, pp. 536-544.
17. Guglielmetti L., Barkane L., Le Du D., Marigot-Outtandy D., Veziris N., Yazdanpanah Y., Kuksa L., Caumes E., Frechet-Jachym M. Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia. Eur. Respir. J., 2018, vol. 51, no. 3, pp. 1702550. https://doi.org/10.1183/13993003.02550-2017
18. Hewison C., Khan U., Bastard M., Lachenal N., Coutisson S., Osso E. et al. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort. Clin. Infect., 2022, vol. 75, no. 6, pp. 1006-1013.
19. Kim C.T., Kim T.O., Shin H. J., Ko Y.C., Hun Choe Y., Kim H.R., Kwon Y.S. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea. Eur. Respir. J., 2018, vol. 51, no. 3, pp. 1702467. https://doi.org/10.1183/13993003.02467-2017
20. Liu X., Ma J., Huang L. et al. Fluoroquinolones increase the risk of serious arrhythmias: a systematic review and meta-analysis. Medicine (Baltimore), 2017, vol. 96, no. 44, pp. e8273.
21. Martín García A., Mitroi C., Mazón Ramos P., García Sanz R., Virizuela J.A., Arenas M., Egocheaga Cabello I., Albert D., Anguita Sánchez M., Arrarte Esteban V.I., Ayala de la Peña F., Bonanand Lozano C., Castro A. et al. Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC. Rev. Esp. Cardiol. (Engl. Ed.), 2021, vol. 74, no. 5, pp. 438-448. https://doi.org/10.1016/j.rec.2020.11.020
22. Tisdale J.E. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can. Pharm. J. (Ott), 2016, vol. 149, no. 3, pp. 139-152. https://doi.org/10.1177/1715163516641136 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860751/)
23. Visseren F.L.J., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Bäck M., Benetos A., Biffi A., Boavida J.M., Capodanno D., Cosyns B., Crawford C., Davos C.H., Desormais I., Di Angelantonio E., Franco O.H. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J., 2021, vol. 42, no. 34, pp. 3227-3337.
24. Zhukova Е., Batyrshina Y. The effects of bedaquiline and fluoroquinolone-based treatment regimens in patients with MDR/XDR-TB on QT prolongation. Eur. Respir. J., 2021, vol. 58, supp. 165, pp. 3337. https://doi.org/10.1183/13993003.
Review
For citations:
Zhukova E.M., Serov O.A. Cardiovascular Risk Factors when Using Modern Chemotherapy Regimens in Comorbid Patients with Multiple Drug-Resistant Tuberculosis. Tuberculosis and Lung Diseases. 2025;103(3):40-46. (In Russ.) https://doi.org/10.58838/2075-1230-2025-103-3-40-46
Views:
792
Email this article 